• News
  • SAN DIEGO
  • BioTech

Evoke's rally fizzles

Solana Beach’s Evoke Pharma Inc. (Nasdaq: EVOK) was the fifth-biggest loser on the Nasdaq board on Monday, as its stock price dipped 5.4 percent to $6.52 per share.

The decline was a reversal of a three-day rally, following the release of the company’s second quarter earnings report last week. Despite Monday’s sharp drop, the stock is still valued higher than it was when the rally began.

Although the company -- still in its startup phase -- lost $3.5 million during the quarter, $2.9 million came from research and development costs in its quest to treat a gastrointestinal disease related to diabetes. The company announced last week that it has launched electrocardiogram testing on healthy volunteers using its proposed treatment, which is currently in Phase 3 testing. The electrocardiogram testing is designed to comply with the Food and Drug Administration’s requirements for new drug applications.

Leave Your Comment

Comments are moderated by SDDT, in accordance with the SDDT Comment Policy, and may not appear on this commentary until they have been reviewed and deemed appropriate for posting. Also, due to the volume of comments we receive, not all comments will be posted.

SDDT Comment Policy: SDDT encourages you to add a comment to this discussion. You may not post any unlawful, threatening, defamatory, obscene, pornographic or other material that would violate the law. All comments should be relevant to the topic and remain respectful of other authors and commenters. You are solely responsible for your own comments, the consequences of posting those comments, and the consequences of any reliance by you on the comments of others. By submitting your comment, you hereby give SDDT the right, but not the obligation, to post, air, edit, exhibit, telecast, cablecast, webcast, re-use, publish, reproduce, use, license, print, distribute or otherwise use your comment(s) and accompanying personal identifying and other information you provide via all forms of media now known or hereafter devised, worldwide, in perpetuity. SDDT Privacy Statement.

User Response
0 UserComments

Leave Your Comment

Comments are moderated by SDDT, in accordance with the SDDT Comment Policy, and may not appear on this commentary until they have been reviewed and deemed appropriate for posting. Also, due to the volume of comments we receive, not all comments will be posted.

SDDT Comment Policy: SDDT encourages you to add a comment to this discussion. You may not post any unlawful, threatening, defamatory, obscene, pornographic or other material that would violate the law. All comments should be relevant to the topic and remain respectful of other authors and commenters. You are solely responsible for your own comments, the consequences of posting those comments, and the consequences of any reliance by you on the comments of others. By submitting your comment, you hereby give SDDT the right, but not the obligation, to post, air, edit, exhibit, telecast, cablecast, webcast, re-use, publish, reproduce, use, license, print, distribute or otherwise use your comment(s) and accompanying personal identifying and other information you provide via all forms of media now known or hereafter devised, worldwide, in perpetuity. SDDT Privacy Statement.

Subscribe Today!